Market research reports on: Pharmaceutical manufacture, cancer, oncology, prevention and treatment, therapeutics, vaccines, clinical studies, drug delivery, immunology, immunotherapy and others.
Let's ConnectInterleukin-2, a Tale of Two Halves: To Suppress or Augment Suppr...
The report provides a detailed description of autoimmune responses and possible ways that drug development can augment immune responses so as to improve antitumor activity and reduce off target effect.This report will assess the latest developments in the IL-2 research and development and explore the novel strategies companies are adopting to augment immune response and avoid off target effects in a wide range of conditions including, metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), Type 1 diabetes (T1D), as a prophylaxis post-transplant and allergic conditions.What's coming: There are more than 200 studies underway evaluating IL-2 based therapies either as a monotherapy or in combination. The key products and companies that we believe are worth watching in this space are summarized.
Markets at a Glance: Pharmaceuticals
The “Market at a Glance Pharmaceuticals” provides an access to all the market share analysis segments of the best-selling and key pharmaceutical reports of BCC Research. This report is a destination for the competitive landscape in the markets that hold a significant stand in the pharmaceuticals sector. Company profiles for all the notable manufacturers in the global pharmaceutical industry are provided as a part of this report.
Nothing Degrading about Saving Lives: E3 Ligands Recruiting New D...
Posttranslational modifications hit prime time in the pharma industry. There probably isn’t a medium sized biopharmaceutical that does not have an active program ongoing, and certainly all of the big pharma companies are running multiple programs, and collaborations, for what we might have previously termed “undruggable targets”. Many of these are for highly unmet needs in neurodegeneration. The properties of the structure that forms between a target, a degrader and an E3 ligase, are under intense investigation. Minor changes affect how the drugs work - this can explain how promiscuous target-binding payloads can achieve super selectivity when transformed into a degrader. These minor alterations can also render the molecule complex not only ineffective, but sometimes toxic. However, clinical results are beginning to write a compellingly effective story – the long and winding history of research into the ubiquitin proteasome may well have more blockbusters in store for us. And cures in a once overlooked corner of the cell machinery architecture.
Colorectal Cancer Therapeutics: Global Markets
The global colorectal cancer therapeutics market should reach $18.5 billion by 2023 from $13.7 billion in 2018 at a compound annual growth rate (CAGR) of 6.1% for the period 2018 to 2023.
High-Throughput Screening: Technologies and Global Markets
The global high-throughput screening (HTS) market should reach $21.1 billion by 2023 from $14.4 billion in 2018 at a compound annual growth rate (CAGR) of 7.9% for the period 2018-2023.
Blood Cancer Therapeutics: Global Markets to 2023
The global market for blood cancer therapeutics should grow from $38.5 billion in 2018 to $64.8 billion by 2023 at a compound annual growth rate (CAGR) of 11.0% from 2018 to 2023.
Brain Tumor Therapeutics: Global Markets to 2023
The global market for brain tumor therapeutics should grow from $1.1 billion in 2018 to reach $2.0 billion by 2023 at a compound annual growth rate (CAGR) of 12.9% for the period of 2018-2023.
Global Cancer Therapeutics Market: Emphasis on Recurrent and Meta...
The global cancer therapeutics market should grow from $128.1 billion in 2018 to $182.0 billion by 2023 at a compound annual growth rate (CAGR) of 7.3% for the period of 2018-2023.
Global Market for Contract Research Organization (CRO) Services
The global market for CRO's across the clinical trial process should grow from $45.5 billion in 2017 to reach $72.3 billion by 2022 at a compound annual growth rate (CAGR) of 9.7% for the period of 2017-2022.
Opioid Drugs: Global Markets to 2023
The global market for opioid drugs should reach $29.8 billion by 2023 from $26.4 billion in 2018 at a compound annual growth rate (CAGR) of 2.5% for the period of 2018-2023.
Antibiotics: Global Markets to 2023
The global antibiotics market should reach $55.8 billion by 2023 from $38.3 billion in 2018 at a compound annual growth rate (CAGR) of 7.8% for the period of 2018-2023.
Lung Cancer Therapeutics: Global Markets
The global market for lung cancer therapeutics should grow from $17.9 billion in 2018 to $26.3 billion by 2023, increasing at a compound annual growth rate (CAGR) of 8.0% from 2018 to 2023.
Checkpoint Inhibitors: Global Markets
The global checkpoint inhibitors market should reach $29.3 billion by 2023 from $14.9 billion in 2018 at a compound annual growth rate (CAGR) of 14.4% for the period of 2018-2023.
Global Viral Vector Manufacturing Markets and Technologies Throug...
The global market for viral vector vaccine manufacturing is expected to increase from $22.9 million in 2017 to nearly $51.2 million in 2022 at a compound annual growth rate (CAGR) of 17.5% for 2017-2022.
Chromatography: A BCC Research Outlook
The global market for chromatography reagents should grow from $10.0 billion in 2018 to $14.2 billion by 2023 at a compound annual growth rate (CAGR) of 7.4% from 2018 through 2023.
Antipsychotic Drugs: Technologies and Global Markets
The global market for antipsychotic drugs should grow from $13.2 billion in 2018 to reach $14.5 billion by 2023 at a compound annual growth rate (CAGR) of 1.9% for the period of 2018-2023.
Lysosomal Disease Treatments: Technologies and Global Markets
The global market for lysosomal storage diseases treatment should grow from $5.1 billion in 2018 to reach $7.6 billion by 2023 at a compound annual growth rate (CAGR) of 8.3% for the period of 2018-2023.
Antiemetics: Technologies and Global Markets
The global market for antiemetics reached $4.1 billion in 2017 and should reach $5.9 billion by 2022, at a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2018-2023.
Cognition and Memory Enhancement Drugs: Technologies and Global M...
The global cognition and memory-enhancing drugs market should reach over $4.2 billion by 2022 from $2.8 billion in 2017 at a compound annual growth rate (CAGR) of 8.7% for the period 2017-2022.
Neuroprotective Agents: Therapeutic Applications and Global Marke...
The global market for neuroprotective agents will grow from $54.4 billion in 2017 to $75.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.8% for the period of 2017-2022.
Antiulcerant Drugs: Global Markets to 2022
The global antiulcerant drugs market will grow from $33.0 billion in 2017 to $37.4 billion by 2022 with a compound annual growth rate (CAGR) of 2.5% for the period of 2017-2022.
The Global Influenza Market
The global influenza market was valued at nearly $5.6 billion in 2017 and is expected to reach nearly $6.5 billion by 2022, increasing at a compound annual growth rate (CAGR) of 3.0% from 2017 through 2022.
Drugs for Urinary Incontinence and Overactive Bladder: Global Mar...
The global drugs for urinary incontinence and overactive bladder market should reach $4.2 billion by 2022 from $3.6 billion in 2017 at a compound annual growth rate (CAGR) of 2.9%, from 2017 to 2022.
Muscle Relaxants: Global Markets to 2022
The global muscle relaxants market totaled $18.4 billion in 2017 and is estimated to reach $24.4 billion by 2022, growing at a compound annual growth rate (CAGR) of 5.8% for the period of 2017-2022.
Anti-Epileptic Drugs: Global Markets to 2022
The global anti-epileptic drugs market totaled $8.4 billion in 2017 and is estimated to reach $9.5 billion by 2022, growing at a compound annual growth rate (CAGR) of 2.7% for the period of 2017-2022.
Choose your License